Evidence map›Paper›PMID 39632986›Full record

ArticleNature cardiovascular research2024

Pharmacological blocking of neutrophil extracellular traps attenuates immunothrombosis and neuroinflammation in cerebral cavernous malformation.

Favour C Onyeogaziri, Ross Smith, Maximiliano Arce, Hua Huang, Iza Erzar, Charlotte Rorsman, Matteo Malinverno, Fabrizio Orsenigo, Veronica Sundell, Dinesh Fernando and 6 more

Abstract read
In one paragraph

Article in Nature cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Favour C OnyeogaziriDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-5742-0474
Ross SmithDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Maximiliano ArceDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0001-6286-7302
Hua HuangDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Iza ErzarDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Charlotte RorsmanDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Matteo MalinvernoVascular Biology Unit, The FIRC Institute of Molecular Oncology Foundation, Milan, Italy.ORCID http://orcid.org/0000-0001-8242-7937
Fabrizio OrsenigoVascular Biology Unit, The FIRC Institute of Molecular Oncology Foundation, Milan, Italy.
Veronica SundellDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Dinesh FernandoDepartment of Biomaterials and Technology/Wood Science, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Geoffrey DanielDepartment of Biomaterials and Technology/Wood Science, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Mika NiemeläDepartment of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Aki LaaksoDepartment of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Behnam Rezai JahromiDepartment of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0003-3937-2816
Anna-Karin OlssonDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Peetra U MagnussonDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. peetra.magnusson@igp.uu.se.ORCID http://orcid.org/0000-0003-1142-854X

Funding

Vetenskapsrådet (Swedish Research Council) 2013-09279Vetenskapsrådet (Swedish Research Council) 2021-01919
6 · The paper itself

Abstract

Cerebral cavernous malformation (CCM) is a neurovascular disease with symptoms such as strokes, hemorrhages and neurological deficits. With surgery being the only treatment strategy, understanding the molecular mechanisms of CCM is crucial in finding alternative therapeutic options for CCM. Neutrophil extracellular traps (NETs) were recently reported in CCM, and NETs were shown to have positive or negative effects in different disease contexts. In this study, we investigated the roles of NETs in CCM by pharmacologically inhibiting NET formation using Cl-amidine (a peptidyl arginine deiminase inhibitor). We show here that Cl-amidine treatment reduced lesion burden, coagulation and endothelial-to-mesenchymal transition. Furthermore, NETs promoted the activation of microglia and fibroblasts, leading to increased neuroinflammation and a chronic wound microenvironment in CCM. The inhibition of NET formation caused endothelial quiescence and promoted a healthier microenvironment. Our study suggests the inhibition of NETs as a potential therapeutic strategy in CCM.

Indexed as

Extracellular TrapsHemangioma, Cavernous, Central Nervous SystemAnimalsCells, CulturedDisease Models, AnimalEnzyme InhibitorsEpithelial-Mesenchymal TransitionFibroblastsHumansMaleMiceMice, Inbred C57BLMicrogliaNeuroinflammatory DiseasesNeutrophilsOrnithineEnzyme InhibitorsN-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amideOrnithine

Identifiers

PMID39632986
PMCPMC11634782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.